SCHEMBL1406131

SCHEMBL1406131

NCC1CCN(CCc2ccc(O)cc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 1/20 0.51
MAOB P27338 1/20 0.51
HRH3 Q9Y5N1 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600688 0.84 HTR2A (0.57)
SCHEMBL22254776 0.84 HRH3 (0.62) CCR3MAOBHRH3L3MBTL1
SCHEMBL3594852 0.83 CCR3 (0.73) CCR3
Hydrochloric Acid SCHEMBL30843800 0.83 KCNH2 (0.56)
Hydrochloric Acid SCHEMBL23124024 0.82 CCR3 (0.71) CCR3
SCHEMBL14100275 0.81 SPHK1 (0.65) CCR3MAOBHRH3
SCHEMBL4700505 0.81 HRH3 (0.62) CCR3HRH3L3MBTL1
SCHEMBL3602416 0.80 MAOB (0.56) CCR3MAOBHRH3
SCHEMBL3590302 0.80 SIGMAR1 (0.69) HRH3
SCHEMBL7407241 0.80 CCR3 (0.82) CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507528-B2 2-alkyl-indazole compounds for the treatment of certain cns-related disorders AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2013-08-13 US disclosed
CN-101558057-B 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders ACRAF 2013-05-01 CN disclosed
US-8415476-B2 Indazole having analgesic activity AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2013-04-09 US disclosed
EP-2099780-B1 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS ACRAF (IT) 2013-01-09 EP disclosed
EP-1622892-B1 INDAZOLES HAVING ANALGESIC ACTIVITY ACRAF (IT) 2011-03-09 EP disclosed
US-20100094015-A1 INDAZOLE HAVING ANALGESIC ACTIVITY AZIENDE CHIM. RIUN. ANGEL. FRA. A.C.R.A.F. S.P.A. (IT) 2010-04-15 US disclosed
US-20100056573-A1 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2010-03-04 US disclosed
US-7662836-B2 Indazole having analgesic activity AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2010-02-16 US disclosed
US-7638534-B2 Use of indazole derivatives for the treatment of neuropathic pain AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2009-12-29 US disclosed
CN-101558057-A 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders ACRAF (IT) 2009-10-14 CN disclosed
EP-2099780-A1 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) 2009-09-16 EP disclosed
CN-100427089-C Use of indazole derivatives for the treatment of neuropathic pain ACRAF (IT) 2008-10-22 CN disclosed
WO-2008061688-A1 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2008-05-29 WO disclosed
US-20070010555-A1 Indazole having analgesic activity AZIENDE CHIM. RUIN. ANGEL. FRA. A.C.R.A.F. S.P.A. (IT) 2007-01-11 US disclosed
EP-1646387-B1 USE OF INDAZOLE DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN ACRAF (IT) 2006-11-15 EP disclosed
US-20060183775-A1 Use of indazole derivatives for the treatment of neuropathic pain AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO S.P.A. (IT) 2006-08-17 US disclosed
CN-1809356-A Use of indazole derivatives for the treatment of neuropathic pain ACRAF (IT) 2006-07-26 CN disclosed
EP-1646387-A1 USE OF INDAZOLE DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) 2006-04-19 EP disclosed
WO-2005013989-A1 USE OF INDAZOLE DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R..A.F. S.P.A. (IT) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056573-A1 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS CYP11B2, CYP1A2, INA CCR3 2769/4885MAOB 65/4885HRH3 348/4885
US-20060183775-A1 Use of indazole derivatives for the treatment of neuropathic pain SCN3A, OPRD1, SCN1A CCR3 350/4885MAOB 1340/4885HRH3 55/4885
US-20100094015-A1 INDAZOLE HAVING ANALGESIC ACTIVITY OPRK1, OPRD1, ACHE CCR3 870/4885MAOB 351/4885HRH3 360/4885
US-20070010555-A1 Indazole having analgesic activity ACHE, CYP3A43, RPL35A CCR3 498/4885MAOB 1095/4885HRH3 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.